October 15, 2008
Investigators present final efficacy and tolerability data for study in children with a new liquid formulation of deferiprone (Ferriprox®)
ApoPharma Inc. today announced the
presentation by investigators of final study data on a new liquid
formulation of the iron chelator deferiprone (Ferriprox®) at the
combined 11th International Conference on Thalassaemia &
Haemoglobinopathies / 13th International TIF Conference for
Thalassaemia Patients & Parents in Singapore from October 8-11,
2008...
June 12, 2008
ApoPharma Inc. highlights presentation at the 13th European Hematology Association meeting
ApoPharma Inc. today announced the
presentation of data from a cross-sectional study of thalassemia
major patients in Italy comparing MRI T2* values and LVEF% in
patients receiving deferiprone (Ferriprox®), desferrioxamine (Desferal®)
or deferasirox (Exjade®) conducted under the auspices of the MIOT
group in Pisa, Italy at the 13th European Hematology Association
meeting...
July 31, 2007
Experts in Thalassemia Convene in Cyprus
World experts in thalassemia convened in Paphos to discuss recent findings of decreased heart
disease and increased survival in patients with the inherited disease, thalassemia major. Cyprus has
one of the highest recorded carrier rates for this genetic disease, a disorder in which children require
blood transfusions every 2-4 weeks to survive.....
May 22, 2007
Ferriprox Newly Launched in Indonesia and the Philippines
Ferriprox has recently been approved and launched in two new
countries in the Pan Pacific. For the approximately 1,000
thalassemia major patients in Indonesia, and 1,800 patients in the
Philippines, there is now an alternative to deferoxamine for the
treatment of iron overload...
March 9, 2007
Thalassaemia brochure available for Patients.
Patient Brochure
March 7, 2007
Archived Webcasts now available for viewing
We have recently added an archived section for previously broadcasted
webcasts. The following are informative webcasts currently available for
viewing...
January 10, 2007
A new video called "Reducing
Myocardial Iron in Thalassaemia" is now available for viewing.
September 20, 2006
Two thirds of of thalassaemia major
patients treated with conventional deferoxamine therapy may be at
risk of serious cardiac complications
Cardiac failure due to iron overload in the heart is the leading
cause of death in thalassaemia major patients. A study was
performed to evaluate the prevalence of myocardial iron overload as
well as decreased heart function in thalassaemia major patients
maintained on deferoxamine therapy...
July 11, 2006
Archived Webcasts now available for viewing
We have recently added an archived section for previously broadcasted
webcasts. The following are informative webcasts currently available for
viewing...
May 31, 2006
Ferriprox now recognized as first-line treatment for thalassaemia
patients in Turkey
Ferriprox®(deferiprone) is now being used as the first-line treatment
for thalassemia major in Turkey. The Turkish government granted
Ferriprox® first-line treatment after several clinical trials have
proven its positive effects through use in monotherapy and
combination therapy for thalassemia patients...
January 9, 2006
New Data Show
Ferriprox® Is More Efficacious Than Deferoxamine In Removing Iron From
The Heart And In Preventing Early Death In Patients With Thalassemia
Results from two new studies demonstrate that treatment with the oral
iron chelator Ferriprox™ (deferiprone) prevents iron-induced heart
disease and significantly reduces the risk of early cardiac death...
March 25, 2005
Cooley's Anemia Press Release
Overwhelming data showing protection of the heart in iron overloaded
patients treated with the oral iron chelator deferiprone
(Ferriprox™)...
March 24, 2004
CPMP positive opinion on extended indication for Ferriprox®
The European Agency for the Evaluation of Medicinal Products Press
Release... |
